AACR Virtual Special Congress, “The Evolving Tumor Microenvironment in Cancer Progression; Mechanisms and Emerging Therapeutic Opportunities” – January 11-12, 2021, brought together experts from diverse fields to thoroughly explore and discuss the topic. Dr. Sahin gave a “Lightning Talk” on the role of LOX in chemoresistance.
“Hollings team marks milestone in progress toward investigational new drug for triple-negative breast cancer” https://hollingscancercenter.musc.edu/news/archive/2024/07/22/lox-inhibitor-for-triple-negative-breast-cancer
A highly potent bi-thiazole inhibitor of LOX rewires collagen architecture and enhances chemoresponse in triple-negative breast cancer https://www.sciencedirect.com/science/article/pii/S2451945624002733?via%3Dihub
We participated in the AACR conference with three distinct poster presentations.
0 Comments